| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 49,720 | 17,500 | 177,880 | 240,030 | 263,700 |
| Sales Growth | +184.11% | -90.16% | -25.89% | -8.98% | +7.30% |
| Net Income | -51,690 | -64,920 | -79,590 | -270,900 | -109,400 |
| Net Income Growth | +20.38% | +18.43% | +70.62% | -147.62% | -142.30% |
Rvl Pharmaceuticals Plc (RVLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
RVL Pharmaceuticals plc is a specialty pharmaceutical company. It focused on the commercialization and development of products which target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. RVL Pharmaceuticals plc, formerly known as Osmotica Pharmaceuticals plc, is based in BRIDGEWATER, N.J.
Fiscal Year End Date: 12/31